logo
Ultraprocessed Foods Tied to Early Signs of Parkinson's

Ultraprocessed Foods Tied to Early Signs of Parkinson's

Medscape08-05-2025

High intake of packaged snacks, hot dogs, sugary sodas, and other ultraprocessed foods (UPFs) was linked to increased risk for early, nonmotor signs of Parkinson's disease (PD), showed new research.
Data analysis of nearly 43,000 individuals showed that those who consumed an average of 11 or more servings of UPFs per day were twice as likely to have at least three prodromal PD features compared with those who had less than three servings per day.
Prodromal traits typically precede diagnosable symptoms of a condition. For PD, these features would precede more characteristic symptoms, such as tremors and movement problems.
Higher UPF consumption was also linked to increased odds for having individual PD prodromal features, including probable rapid eye movement sleep behavior disorder (pRBD), body pain, depressive symptoms, and constipation.
Xiang Gao, MD, PhD
The findings suggest that 'a healthy dietary pattern — high in fruits and vegetables and low in UPF — could be beneficial against risk of PD, an incurable neuro-degenerative disease,' co-investigator Xiang Gao, MD, PhD, dean and distinguished professor, Institute of Nutrition, Fudan University, Shanghai, China, told Medscape Medical News.
The study was published online on May 7 in Neurology.
Future Risk Assessments
Earlier studies by Gao's team showed that overall poor diet quality was associated with increased risk for PD.
In addition, 'UPF, which is strongly associated with poor diet quality, has recently been shown to be associated with dementia, another major neurodegenerative disease. However, the relation between UPF and PD remained unknown,' he said.
The investigators analyzed data on 42,853 participants (mean age, 47.8 years; 58.6% women) without PD from the Nurses' Health Study and Health Professionals Follow-Up Study.
Repeated food frequency questionnaires were used to assess UPF consumption. Investigators included types of UPFs in the analysis, such as sauces, spreads, or condiments; packaged sweets; snacks or desserts; artificially- or sugar-sweetened beverages; animal-based products; yogurt- or dairy-based desserts; and packaged savory snacks.
In addition, data were evaluated on seven PD prodromal features: pRBD, constipation, body pain, depressive symptoms, reduced ability to smell (hyposmia), excessive daytime sleepiness, and impaired color vision.
'Growing Body of Evidence'
After adjusting for factors such as age, alcohol and caffeine intake, physical activity, and body mass index, participants with the highest cumulative average consumption (≥ 11 servings/d) were more than twice as likely to have more than three prodromal features compared with those with the lowest consumption (< 3 servings/d) (odds ratio [OR], 2.5; P < .0001).
Similar results were found in the highest consumption group for having a combination of all the prodromal features except for constipation (OR, 2.0; P for trend < .0001), as well as for a combination of just constipation, pRBD, and hyposmia (OR, 2.5; P for trend = .008).
Those who reported the highest UPF consumption also had increased risk for the individual prodromal features of body pain (adjusted OR [aOR], 1.7), constipation (aOR, 1.6), depressive symptoms (aOR, 1.5), and pRBD (aOR, 1.2).
Drilling down even more, greater odds for prodromal features were associated with higher intake of the following specific types of UPF: Packaged sweet snacks/desserts (OR, 1.6), sweetened beverages (OR, 1.5), sauces/spreads/condiments (OR, 1.4), animal-based products (OR, 1.4), yogurt-/dairy-based desserts (OR, 1.3), and packaged savory snacks (OR, 1.3). Ultraprocessed breads/cereals and ready-to-eat/heat-mixed dishes did not have significant associations.
'Overall, our study adds to the growing body of evidence to support the adverse effects of UPF consumption on neurodegenerative diseases,' the investigators wrote.
However, 'more studies are needed to confirm our finding that eating less processed food may slow down the earliest signs' of PD, Gao added in a release.
Findings Reinforce 'Crucial Message'
Commenting for Medscape Medical News, Daniel J. van Wamelen, PhD, clinical senior lecturer in neuroscience and honorary consultant neurologist at King's College London, London, England, noted that the study was well-designed overall, included a large number of participants, and addressed an interesting and useful topic.
However, 'the results should be interpreted with some caution, given the limitations,' said van Wamelen, who was not involved with the research.
'The main message in my opinion is that external factors, such as ultraprocessed foods, may be associated with an increased presence of certain nonmotor symptoms and, pending data from future follow-up, might be shown to form a risk factor for Parkinson's disease,' he said.
van Wamelen added separately in a press statement from the nonprofit Science Media Centre (SMC) that conditions such as constipation and sleep disturbances are common among the general population. 'It is important to highlight that the symptoms examined in this study are possible early signs of [PD], not definitive indicators that someone will go on to develop it,' he said in the statement.
In an accompanying editorial, Maria Maraki, PhD, University of Athens, Athens, Greece, and Nikolaos Scarmeas, MD, Columbia University, New York City, wrote that the study results 'reinforce general health dietary guidelines' that emphasize minimal consumption of UPFs and are similar to previous studies.
They suggested that potential links between UPFs and PD itself, rather than just its prodromal phase, should be the focus of future research.
'The prevention of neurodegenerative diseases may begin at the dinner table. Dietary choices today may shape brain health in the decades to come,' the editorialists wrote.
'This study reinforces a crucial message: excessive UPF consumption not only is a risk factor for metabolic diseases but may also accelerate neurodegenerative processes and associated symptoms,' they added.
Eef Hogervorst, PhD, professor of psychology at Loughborough University, Loughborough, England, also commented on the findings in the SMC statement, noting 'it seemed strange' that the investigators categorized such things as pancakes, cream, coffee, distilled alcohol, and sandwiches made with beef, lamb, chicken, or turkey as non-UPFs.
'So this study may be affected by UPF categorization as a predictor,' said Hogervorst, who was not involved with the research. She also pointed out that because the study population consisted of 'mainly white health professionals,' the results may not be generalizable to all populations.
This study was funded by the National Institute of Neurological Disorders and Stroke, the Shanghai municipal public system, the National Natural Science Foundation of China, and the China Postdoctoral Science Foundation.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

Yahoo

time2 hours ago

  • Yahoo

China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China, following recent granting of Priority Review by CDE Additional applications planned in the US and other markets around the world Not intended for UK-based media DARMSTADT, Germany, June 10, 2025--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company's application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., also has been granted breakthrough therapy designation (BTD) by the NMPA. "With the acceptance of our application for pimicotinib and the initiation of the priority review, we aim to offer patients in China the first approved systemic therapy for TGCT, addressing a tremendous unmet need in this country," said Hong Chow, Head of China and International, Healthcare business of Merck KGaA, Darmstadt, Germany. "Pimicotinib has demonstrated the ability to not only shrink tumors that affect their joints but also improve outcomes like mobility, pain and stiffness, highlighting its potential to be a best-in-class treatment for TGCT. In parallel, we are working to file a New Drug Application to the US Food and Drug Administration, with additional filings planned in other markets." TGCT is a locally aggressive and often recurring tumor of the joints that can cause high morbidity associated with swelling, pain, stiffness, and limited mobility of the affected joints, significantly impacting daily activities and quality of life in the primarily working-age population that it affects. If left untreated or in recurrent cases, TGCT can result in irreversible damage to the bone, joint and surrounding tissues. This highlights the need for well-tolerated and effective systemic treatments that can impact tumor growth while relieving the symptoms of the disease. The application is based on results from Part 1 of the global Phase 3 MANEUVER study, in which once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) compared with placebo at week 25 (54.0% vs. 3.2% for placebo; p<0.0001). The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain. The data were presented earlier this month at the 2025 ASCO Annual Meeting. About MANEUVERThe pivotal Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pimicotinib in patients with TGCT who require systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy. The study is being conducted by Abbisko Therapeutics in China (n=45), Europe (n=28), and the US and Canada (n=21). In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of pimicotinib (n=63) or placebo (n=31) for 24 weeks. The primary endpoint is objective response rate (ORR) at week 25, as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review in the intent-to-treat (ITT) population. Secondary endpoints include tumor volume score, active range of motion, stiffness by Numeric Rating Scale (NRS), pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS). After the double-blind Part 1, eligible patients could continue to the open-label Part 2 for up to 24 weeks of dosing, results of which are expected in mid-2025. Patients who complete Part 2 may then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up. About Pimicotinib (ABSK021)Pimicotinib (ABSK021), which is being developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib was recently granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of patients with tenosynovial giant cell tumor (TGCT) who require systemic therapy. Pimicotinib has been granted breakthrough therapy designation (BTD) by China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck KGaA, Darmstadt, Germany, holds worldwide commercialization rights for pimicotinib. Advancing the Future of Cancer CareAt Merck KGaA, Darmstadt, Germany, we strive every day to improve the futures of people living with cancer. Building on our 350-year global heritage as pharma pioneers, we are focusing our most promising science to target cancer's deepest vulnerabilities, pursuing differentiated molecules to strike cancer at its core. By developing new therapies that can help advance cancer care, we are determined to create a world where more cancer patients will become cancer survivors. Learn more at About Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to to register for your online, change your selection or discontinue this service. View source version on Contacts Media Relations Phone: +1 (781) 427-4351 Investor Relations Phone: +49 6151 72-3321 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore

Yahoo

time2 hours ago

  • Yahoo

ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore

SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities. The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023.[1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030,[2] these efforts aim to better position Singapore-based innovations to scale and enter new markets. Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem. The partnership will focus on several key areas: Fostering new ventures from research: A*STAR and ClavystBio will jointly identify promising research and technologies to venture build new MedTech companies. A*STAR will contribute deep scientific expertise and structured venture creation support, while ClavystBio will provide access to venture and growth capital, expert guidance, and its extensive network to launch and scale these early-stage companies. Advancing MedTech product development: MedTech Catapult will support the development of medical devices through engineering design, prototyping, and manufacturing translation, while ClavystBio will draw on its investment and industry relationships to explore potential commercial pathways for promising innovations. Accelerating commercial readiness in diagnostics and digital health: DxD Hub and ClavystBio will shape ventures in this space with strong commercial potential. DxD Hub will bring technical and productisation expertise — including in AI-powered software, multi-omics, and point-of-care diagnostics — to refine innovations for commercial viability. ClavystBio will contribute its venture investing and venture building expertise to drive commercialisation. Strengthening Singapore's MedTech ecosystem: To support long-term sector growth, the partners will assess Singapore's MedTech manufacturing, design, and regulatory support landscape. MedTech Catapult will lead efforts to map ecosystem capabilities and identify gaps, while ClavystBio will explore investment opportunities in companies with specialised technologies that can strengthen Singapore's MedTech value chain. "This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success. "A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore." [1] Speech by SMS Low Yen Ling at the MedTech Forum[2] Singapore's MedTech sector and locally made medical devices punching above their weight | Singapore EDB About ClavystBio ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit About Diagnostics Development Hub (DxD Hub) The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit About MedTech Catapult MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing. View original content to download multimedia: SOURCE ClavystBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

NASA astronaut's first ISS time-lapse is a real stunner
NASA astronaut's first ISS time-lapse is a real stunner

Digital Trends

time4 hours ago

  • Digital Trends

NASA astronaut's first ISS time-lapse is a real stunner

NASA astronaut Jonny Kim has shared his first-ever time-lapse from aboard the International Space Station (ISS) — and it's a real stunner. The dramatic 68-second clip shows a changing view of Earth as the space-based facility orbits our planet at an altitude of about 250 miles. Recommended Videos 'My first time-lapse,' Kim wrote in a social media post that included the video (below). Kim said he managed to nail it thanks to some time-lapse tips shared by fellow astronaut Nichole Ayers. 'After seeing the result, I told her this felt like fishing,' Kim wrote. 'Prepping the camera, the angle, the settings, the mount, then setting your timer and coming back to hope you got a catch. And after catching my first fish, I think I'm hooked.' My first time-lapse. Thanks to some instruction and tips from @Astro_Ayers, I caught my first aurora. After seeing the result, I told her this felt like fishing. Prepping the camera, the angle, the settings, the mount, then setting your timer and coming back to hope you got a… — Jonny Kim (@JonnyKimUSA) June 6, 2025 The video shows the space station flying into the night, with city lights in Asia and Australia visible far below, and bright stars shining in the far distance. A short while later, a gorgeous aurora appears over the horizon before filling much of the frame. Toward the end of the clip, one of the station's solar arrays also come into view. Auroras are natural light displays in Earth's sky, caused by charged particles from the sun colliding with the Earth's magnetic field and atmosphere. While also viewable from parts of Earth, astronauts on the ISS can also enjoy a unique view of this natural wonder. Indeed, for most astronauts, witnessing auroras is one of the highlights of their time in orbit. Earlier this year, another NASA astronaut, Don Pettit, shared a dramatic view of an aurora, captured as the ISS flew directly over it. Kim arrived at the space station with two Russian cosmonauts after launching aboard a Soyuz spacecraft in April this year. With another four months of his mission left to run, hopefully the American will have time to create more clips similar to his first outstanding effort.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store